Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot, Andrea Necchi, Se Hoon Park, +18

New England Journal of Medicine

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, +16

Journal of Clinical Oncology

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Shubham Pant, Martin Schüler, Gopa Iyer, +103

The Lancet Oncology

Fgfr AlterationsMedicinePathologyAdvanced Solid TumoursFibroblast Growth Factor +5

Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia

Mahesh N. Samtani, An Vermeulen, Kim Stuyckens

Clinical Pharmacokinetics

PsychiatryPsychotic DisorderMedicinePsychopharmacologySchizophrenia +5

Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients

Xu S. Xu, Charles J. Ryan, Kim Stuyckens, +8

Clinical Cancer Research

Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer

Kim Stuyckens, Fred Saad, Xu Steven Xu, +7

Clinical Pharmacokinetics

UrologyMedicinePharmacologyPopulation Pharmacokinetic AnalysisPharmacotherapy +4

The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer

Carla M. Prado, Vickie E. Baracos, Jingjie Xiao, +5

Applied Physiology Nutrition and Metabolism

Muscle TissueBody CompositionBody MassMedicineCancer Management +11

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes

Xu Steven Xu, Kenneth Todd Moore, Paul Burton, +6

British Journal of Clinical Pharmacology

Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (<i>FGFRalt</i>) in RAGNAR: Interim analysis (IA) results.

Yohann Loriot, Martin Schüler, Gopa Iyer, +17

Journal of Clinical Oncology

ImmunologyPathologyAdvanced Solid TumorsTumor Agnostic EfficacyOncology +14

Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.

Rastislav Bahleda, Rodrigo Dienstmann, Bárbara Adamo, +12

Journal of Clinical Oncology

PathologyAdvanced Solid TumorsCancer BiologyTumor BiologyOncology +16